日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. DLL4 (Navicixizumab Biosimilar) Recombinant Monoclonal Antibody

DLL4 (Navicixizumab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA878862MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    DLL4 (Navicixizumab Biosimilar Antibody) 重組單克隆抗體是一種靶向人Delta樣配體4（DLL4），其別名為AOS6 antibody、Delta 4 antibody、Delta-like 4、Dll4 antibody、Navicixizumab等，可特異性識別由重組人DLL4蛋白免疫產(chǎn)生的抗原，主要與人類種屬發(fā)生反應(yīng)。 Navicixizumab Biosimilar Antibody作為靶向DLL4抗體，Navicixizumab的類似物，通過抑制Notch通路，可阻斷腫瘤新生血管的異常形成，改善腫瘤微環(huán)境，從而抑制腫瘤生長和轉(zhuǎn)移。目前，其相關(guān)臨床應(yīng)用主要聚焦于實體瘤治療領(lǐng)域，如結(jié)直腸癌、非小細(xì)胞肺癌等，旨在評估其單藥或聯(lián)合化療、免疫治療的安全性和有效性，為晚期癌癥患者提供新的治療選擇。 該抗體憑借高度的特異性和種屬反應(yīng)性，成為研究DLL4生物學(xué)功能的重要工具。它助力探索DLL4在胚胎發(fā)育、血管生成、腫瘤發(fā)生等生理和病理過程中的作用機制。此外，作為Navicixizumab的類似抗體，其在藥物研發(fā)中可用于活性對比研究，為其的質(zhì)量控制和臨床替代提供實驗依據(jù)，推動靶向治療藥物的普及和應(yīng)用。
  • Uniprot No.：
  • 基因名：
  • 別名：
    AOS6 antibody; Delta 4 antibody; delta 4 precursor antibody; Delta ligand 4 antibody; delta ligand 4 precursor antibody; Delta like 4 antibody; Delta like 4 homolog antibody; Delta like 4 protein antibody; Delta like canonical Notch ligand 4 antibody; Delta like protein 4 antibody; Delta-like 4；Drosophila antibody; Delta-like protein 4 antibody; Delta4 antibody; DLL 4 antibody; Dll4 antibody; DLL4_HUMAN antibody; Drosophila Delta homolog 4 antibody; hdelta2 antibody; Homeobox protein DLL-4 antibody; MGC126344 antibody; Notch ligand delta 2 antibody; Notch ligand DLL4 antibody; Notch ligand DLL4 precursor antibody; XDLL-4 antibody; Navicixizumab
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human DLL4 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Involved in the Notch signaling pathway as Notch ligand. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate.
  • 基因功能參考文獻(xiàn)：
    1. These data indicate that DLL4 represents a new prognostic biomarker for nonsmall cell lung cancer , and DLL4 overexpression inhibits cell proliferation and metastasis in vitro. PMID: 30226615
    2. Study demonstrates that DLL4 is important in regulating the tumour growth of hepatitis B virus (HBV)-associated hepatocellular carcinoma as well as the neovascularization and suppression of HBV replication. PMID: 30228780
    3. this study revealed that DLL4 has pathophysiological roles on the progression of esophagus cancer cells, including migration, invasion and apoptosis, which indicated that DLL4 may be considered as a potent therapeutic target for the treatment of malignant esophageal cancer. PMID: 29749499
    4. The regulation of DLL4 by the LDB2 complex provides a novel mechanism of DLL4 transcriptional control that may be exploited to develop therapeutics for aberrant vascular remodeling. PMID: 28946938
    5. Data show that Delta-like 4 (DLL4) and Jagged1 (JAG1) displayed equal potency in stimulating Notch target genes in HMEC-1 dermal microvascular endothelial cells but had opposing effects on sprouting angiogenesis in vitro. PMID: 28445154
    6. epigenetic silencing and TP53 mutation have an effect on the expression of DLL4 in human cancer stem disorder PMID: 27542210
    7. the Notch signaling and atherosclerosis relevant markers in lesions from femoral arteries of symptomatic peripheral artery disease patients, were characterized. PMID: 28472949
    8. Data suggest that Numb acts as a Notch antagonist by controlling intracellular destination and stability of the Notch ligand Delta-like 4 (DLL4) through a post-endocytic sorting process; Numb negatively controls DLL4 plasma membrane recycling through well-documented recycling regulator protein AP1. PMID: 29042443
    9. Results show that DLL4 is involved in SYNJ2BP-induced hepatocellular carcinoma (HCC) development though activating its pathway. PMID: 27440153
    10. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with gallbladder cancers. PMID: 27174628
    11. We show that GIT1, which also contains an ANK domain, inhibits the Notch1-Dll4 signaling pathway by competing with Notch1 ANK domain for binding to RBP-J in stalk cells PMID: 27926858
    12. Results provide evidence that DLL4 is associated with gastric cancer stem/progenitor cells (GCSPCs), and its expression impacts CSPC stemness characteristics associated with the Notch-1 pathway including self-renewal, differentiation, proliferation, and tumor formation. PMID: 27891816
    13. The authors present novel structures of human ligands Jagged2 and Delta-like4 and human Notch2, together with functional assays, which suggest that ligand-mediated coupling of membrane recognition and Notch binding is likely to be critical in establishing the optimal context for Notch signalling. PMID: 28572448
    14. Overexpression of DLL4 could significantly attenuate the cytotoxic effects of docetaxel in MCF-7 cells by increasing Bcl-2 expression, while decreasing Bax expression, apoptosis rate and DNA damage PMID: 27334972
    15. In gastric epithelial cells co-cultured with Helicobacter pylori, the expression level of the ligand DLL4 was found to be significantly increased. PMID: 27073072
    16. Low DLL4 abundance in tumour cells may predict the benefit from adjuvant gemcitabine therapy after PDAC resection. PMID: 27755532
    17. Angiogenesis in Infantile haemangioma (IH) appears to be controlled by DLL4 within the endothelium in a VEGF-A isoform-dependent manner, and in perivascular cells in a VEGF-independent manner. The contribution of VEGF-A isoforms to disease progression also indicates that IH may be associated with altered splicing. PMID: 26957058
    18. Dll4 modulates liver inflammatory response by down-regulating chemokine expression PMID: 27171900
    19. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with pancreatic ductal carcinoma. PMID: 27919854
    20. Data show that the IgA/delta-like protein 4 (Delta-4)/Notch receptor (Notch) axis is not observed in IgG-dendritic cells (DCs). PMID: 27117596
    21. Data suggest that the vascular DLL4-Notch4 signaling and VEGF signaling complementing each other plays an important role in the progression of tumor angiogenesis in primary glioblastoma. PMID: 26472724
    22. our data indicate that high DLL4 expression predicts pelvic lymph node metastasis and poor survival in cervical cancer. Therefore, DLL4 may be a potential clinical diagnostic marker for patients with early-stage cervical cancer. PMID: 26546434
    23. Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling PMID: 26870802
    24. DLL4 and JAG1 may have opposing effects on tumor angiogenesis in glioblastoma. PMID: 26546995
    25. Expression of D114 in the vessels of dermal microvasculature was shown to increase from 20 weeks of gestation to 20 years. PMID: 27487663
    26. Data indicate the role for altered forkhead box C2 (FoxC2)-Delta-like ligand 4 (Dll4)signaling in structural alterations of saphenous veins in patients with varicose veins. PMID: 26808710
    27. Antagonism of the DLL4-Notch signaling pathway might provide a potential therapeutic approach for breast cancer treatment by preventing angiogenesis. PMID: 26739060
    28. Activation of Dll4/Notch signaling led to increased expression of ephrin-B2 and subsequent inhibition of endothelial progenitor cells activity. PMID: 26212082
    29. DLL4 is a unique functional molecule of human circulating dendritic cells critical for directing Th1 and Th17 differentiation PMID: 26712946
    30. The expression of DLL4 was positively correlated with CD105-labeled MVD. PMID: 25986715
    31. The detection of Notch1 and Delta-like 4 expression in peripheral blood lymphocytes of renal transplant recipients can serve as a positive indicator for evaluating the diagnosis and treatment efficacy of the AR reaction. PMID: 26070613
    32. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. PMID: 25833803
    33. DLL4 and VEGFA expression was closely related to tumour diameter, clinical stage, histological grade and lymph node metastasis. PMID: 26111775
    34. DLL4/Notch1 and BMP9 interdependent signaling induces endothelial cell quiescence via P27KIP1/thrombospondin pathway. PMID: 26471266
    35. Overexpression of DLL4 is associated with thyroid tumor invasion and metastasis. PMID: 26241546
    36. Macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells. PMID: 26404485
    37. Heterozygous Loss-of-Function Mutations in DLL4 Cause Adams-Oliver Syndrome. PMID: 26299364
    38. IL-23 could promote migration of human ESCC cells by activating DLL4/Notch1 signaling pathway PMID: 26062426
    39. expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer PMID: 24949865
    40. Dormant Dbf4 mRNA in immature GV oocytes is recruited by cytoplasmic polyadenylation during oocyte maturation and is dependent on MPF activity via its cytoplasmic polyadenylation element (CPE) PMID: 25348865
    41. High DLL4 expression is associated with T acute lymphoblastic leukemia. PMID: 25355291
    42. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture PMID: 25139440
    43. Dll4 expression is up-regulated in clear cell renal cell carcinoma patients, and predicts poor prognosis. PMID: 24966922
    44. Dengue virus up-regulates expression of notch ligands Dll1 and Dll4 through interferon-beta signalling pathway. PMID: 25041739
    45. Our data suggest that renal cell carcinoma progression is caused in part by activated DLL4/Notch signaling, interaction of endothelium and cells PMID: 24931473
    46. these results suggest that high expression of DLL4 is associated with axillary lymph node metastasis and a poor prognosis in breast cancer, suggesting its value as a diagnostic marker for breast cancer. PMID: 25260720
    47. These findings indicate a potential role for the Notch-1-Dll4 signaling pathway in foreign body-induced granulomatous reactions PMID: 24394305
    48. High expression of DLL4 is associated with metastasis in breast cancer. PMID: 24696220
    49. findings suggest that ADAM10/Dll4 signaling is a major signaling pathway in ECs driving inflammatory events involved in inflammation and immune cell recruitment PMID: 25130545
    50. Dll4-containing exosomes increase endothelial cell motility while suppressing their proliferation. PMID: 24504253

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Adams-Oliver syndrome 6 (AOS6)
  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Expressed in vascular endothelium.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 2910

    OMIM: 605185

    KEGG: hsa:54567

    STRING: 9606.ENSP00000249749

    UniGene: Hs.511076



×
生命科學(xué)計算平臺